Ozmosi | DS-1971 Drug Profile

Product Description

A highly potent, selective NaV1.7 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32392056/)

Mechanisms of Action: NaV1.7 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Radiculopathy|Spinal Stenosis|Neuralgia|Neuropathic Pain

Phase 1: Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT02564861	DS1971-A-E106	P1	Completed	Healthy Volunteers	2015-12-01	2024-02-16	Primary Endpoints\|Treatments
NCT02473627	DS1971-A-E105	P1	Completed	Healthy Volunteers	2015-07-01	2024-02-16	Primary Endpoints\|Treatments
NCT02266940	DS1971-A-E104	P1	Completed	Healthy Volunteers	2015-01-01	2024-02-16	Primary Endpoints\|Treatments
NCT02261376	DS1971-A-E103	P1	Completed	Healthy Volunteers	2014-11-01	2024-02-16	Primary Endpoints\|Treatments
NCT02190058	DS1971-A-E102	P1	Completed	Healthy Volunteers	2014-11-01	2024-02-16	Primary Endpoints\|Treatments
NCT02107885	DS1971-A-E101	P1	Completed	Healthy Volunteers	2014-07-01	2024-02-16	Primary Endpoints\|Treatments
JapicCTI-163193	JapicCTI-163193	P2	Terminated	Spinal Stenosis\|Radiculopathy	2017-03-31
NCT02673866	DS1971-A-U202	P2	Withdrawn	Neuropathic Pain\|Neuralgia	2017-01-01	2024-02-16

Recent News Events

Date	Type	Title
12/01/2023	PubMed	Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css-MRTpo method and chimeric mice with humanised livers.
01/01/2023	PubMed	Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective Na(V)1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver.
03/01/2022	PubMed	CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective Na(V)1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

DS-1971

Alternative Names: ds-1971, ds1971, ds 1971, ds1971a, ds-1971a Clinical Status: Inactive Latest Update: 2023-12-01 Latest Update Note: PubMed Publication